GCA
DGX icon

Genesee Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Genesee Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
2,407
+10
+0.4% +$1.96K 0.16% 103
2026
Q1 		$470K Buy
2,397
+11
+0.5% +$2.14K 0.2% 88
2025
Q4 		$414K Buy
2,386
+9
+0.4% +$1.64K 0.17% 88
2025
Q3 		$453K Buy
2,377
+12
+0.5% +$2.13K 0.2% 83
2025
Q2 		$425K Buy
2,365
+11
+0.5% +$1.91K 0.19% 82
2025
Q1 		$398K Buy
2,354
+11
+0.5% +$1.81K 0.2% 86
2024
Q4 		$353K Buy
2,343
+11
+0.5% +$1.71K 0.16% 93
2024
Q3 		$362K Buy
2,332
+12
+0.5% +$1.79K 0.17% 88
2024
Q2 		$318K Buy
2,320
+13
+0.6% +$1.78K 0.16% 90
2024
Q1 		$307K Buy
2,307
+12
+0.5% +$1.56K 0.17% 87
2023
Q4 		$316K Buy
2,295
+14
+0.6% +$1.84K 0.2% 78
2023
Q3 		$278K Buy
2,281
+11
+0.5% +$1.47K 0.2% 77
2023
Q2 		$319K Buy
2,270
+11
+0.5% +$1.52K 0.22% 68
2023
Q1 		$320K Buy
2,259
+10
+0.4% +$1.43K 0.23% 65
2022
Q4 		$352K Buy
2,249
+48
+2% +$6.9K 0.26% 62
2022
Q3 		$270K Buy
2,201
+11
+0.5% +$1.45K 0.21% 71
2022
Q2 		$291K Buy
2,190
+10
+0.5% +$1.36K 0.2% 76
2022
Q1 		$298K Buy
2,180
+9
+0.4% +$1.25K 0.16% 87
2021
Q4 		$376K Buy
2,171
+10
+0.5% +$1.52K 0.18% 79
2021
Q3 		$314K Buy
+2,161
New +$316K 0.15% 86
2021
Q2 		– Sell
-2,141
Closed -$275K – 66
2021
Q1 		$275K Buy
2,141
+9
+0.4% +$1.11K 0.16% 76
2020
Q4 		$254K Buy
2,132
+10
+0.5% +$1.22K 0.17% 72
2020
Q3 		$242K Buy
2,122
+9
+0.4% +$1.06K 0.2% 67
2020
Q2 		$240K Buy
+2,113
New +$224K 0.22% 64
2020
Q1 		– Sell
-2,091
Closed -$223K – 78
2019
Q4 		$223K Buy
2,091
+10
+0.5% +$1.04K 0.19% 63
2019
Q3 		$222K Buy
2,081
+11
+0.5% +$1.13K 0.21% 64
2019
Q2 		$210K Buy
+2,070
New +$199K 0.21% 62

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Genesee Capital Advisors's DGX Position: Q2 2026 in Review

Genesee Capital Advisors increased its Quest Diagnostics (DGX) stake by 0.42% in Q2 2026, buying an estimated $1.96K and bringing the position to 2,407 shares worth $510K. The position accounts for 0.16% of the portfolio, ranked #103.

Genesee Capital Advisors first reported a position in DGX in Q2 2019 and has held it in 27 quarters since. 1,108 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Genesee Capital Advisors held 2,407 shares of Quest Diagnostics worth $510K as of Q2 2026.
  • Genesee Capital Advisors bought 10 Quest Diagnostics shares in Q2 2026, an estimated $1.96K.
  • Quest Diagnostics made up 0.16% of Genesee Capital Advisors's portfolio in Q2 2026, its #103 holding.
  • Genesee Capital Advisors first reported a position in Quest Diagnostics in Q2 2019 and has held it in 27 quarters since.
  • 1,108 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Genesee Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.